Why Trevi Therapeutics (TRVI) Is Advancing Today

Drug maker Trevi Therapeutics (TRVI) is climbing 4.5% after investment bank Stifel raised its price target on the name to $12 from $8. Stifel maintained a Buy rating on the shares.

Why Stifel Is More Bullish on TRVI

With Trevi poised to soon announce data from a trial of its Haduvio drug as a treatment for refractory chronic cough (RCC), Stifel predicts that the readout will be positive. Moreover, Stifel noted that Hadvio, a mixed opioid drug, has demonstrated the ability to effectively treat idiopathic pulmonary fibrosis-related chronic cough (IPF-CC). The latter condition has not been improved by other drugs, Stifel noted.

A scientist in the lab, researching the development of biopharmaceutical monoclonal antibody drugs.

Also importantly, Stifel believes that, if Haduvio proves to be an effective treatment for RCC, it could ultimately be used to treat other types of moderate-to-severe coughs.

Additional Information About TRVI

In December, the company disclosed that it would not have to alter the sample size of a Phase 2b study of Haduvio as a treatment for chronic cough in patients with idiopathic pulmonary fibrosis. Topline data on the trial is due out in the first half of 2025.

The Recent Price Action of TRVI Stock

In the last month, the shares have jumped 19%, while they have soared 75% in the last three months.

While we acknowledge the potential of TRVI, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TRVI but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ ALSO 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock

Disclosure: None. This article is originally published at Insider Monkey.